Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT00349024 Active, not recruiting - Pain Clinical Trials

Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer

Start date: July 2005
Phase: N/A
Study type: Interventional

RATIONALE: Polyvinylpyrrolidone-sodium hyaluronate gel may lessen the pain of oral mucositis, or mouth sores, in patients undergoing treatment for cancer. PURPOSE: This clinical trial is studying how well polyvinylpyrrolidone-sodium hyaluronate gel works in reducing pain from oral mucositis in young patients with cancer.

NCT ID: NCT00348790 Completed - Sarcoma Clinical Trials

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Start date: May 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with recurrent or progressive meningioma.

NCT ID: NCT00340054 Completed - Clinical trials for Brain and Central Nervous System Tumors

Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields

Start date: October 2005
Phase: N/A
Study type: Observational

RATIONALE: Electric and magnetic fields may increase the risk of cancer. Developing interview questions that accurately estimate a person's exposure to electric and magnetic fields may help doctors learn about the long-term effects of workplace exposure. PURPOSE: This clinical trial is developing interview questions that can be used in estimating workplace exposure to electric and magnetic fields.

NCT ID: NCT00337207 Completed - Clinical trials for Brain and Central Nervous System Tumors

Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

Start date: March 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progressive glioma.

NCT ID: NCT00331526 Completed - Clinical trials for Brain and Central Nervous System Tumors

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

Start date: February 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells, including lymphokine-activated killer cells, to kill tumor cells. Giving cellular adoptive immunotherapy during or after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well cellular adoptive immunotherapy works in treating patients with glioblastoma multiforme.

NCT ID: NCT00329589 Completed - Clinical trials for Head and Neck Cancer

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Start date: September 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.

NCT ID: NCT00328458 Completed - Clinical trials for Head and Neck Neoplasms

EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

Start date: February 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.

NCT ID: NCT00313599 Completed - Breast Cancer Clinical Trials

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Start date: February 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. Lapatinib may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving lapatinib together with paclitaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when given together with paclitaxel in treating patients with advanced solid tumors.

NCT ID: NCT00313521 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors

Start date: June 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well thiotepa works together with radiation therapy in treating young patients with newly diagnosed malignant brain tumors.

NCT ID: NCT00304031 Completed - Clinical trials for Brain and Central Nervous System Tumors

Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Start date: January 2006
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known which schedule of temozolomide when given together with radiation therapy is more effective in treating glioblastoma or gliosarcoma. PURPOSE: This randomized phase III trial is studying two different schedules of temozolomide to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed glioblastoma or gliosarcoma.